Inovio Pharmaceuticals Equity 2024

Inovio Pharmaceuticals Aktienanalyse

What does Inovio Pharmaceuticals do?

Inovio Pharmaceuticals Inc. is a US biotechnology and pharmaceutical company specializing in the development of DNA vaccines and immunotherapies. It was founded in 1979 by Dr. Joseph Kim and is headquartered in Plymouth Meeting, Pennsylvania. Inovio began working on DNA-based vaccines in the late 1990s and developed the Electroporation technology, which facilitates the introduction of DNA molecules into cells. The company has expanded its capabilities over the years and is able to generate immune responses against a variety of viruses and bacteria. They have also made advancements in using their technology to combat cancer. Inovio's business model is based on licensing technologies and collaborating with partners such as pharmaceutical companies, government agencies, and academic institutions. They also offer services for the development and production of DNA-based vaccines for academic and industrial customers. Inovio is divided into different divisions, including DNA vaccines for infectious diseases and oncology, platform technology, and cancer immunotherapy. They offer a wide range of DNA vaccines for infectious diseases such as HPV, HIV, hepatitis B and C, as well as Lassa fever and Ebola. Inovio has also made significant progress in the development of DNA-based immunotherapies for cancer, using Electroporation technology to train and activate T-cells against cancer cells. In terms of products, Inovio has various products in different stages of clinical development, but they have not yet received FDA approval for any of their products. However, they have successfully conducted clinical trials for vaccines such as HPV, which has shown 90% efficacy against the virus. In conclusion, Inovio is a specialized company in the development of DNA-based vaccines and immunotherapy for cancer. Their Electroporation technology has led to significant breakthroughs, and they continue to pursue partnerships and further development. With their focus on research and development and advancing their technologies, it seems that Inovio is on a path of continued success. Inovio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Inovio Pharmaceuticals's Equity

Inovio Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Inovio Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Inovio Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Inovio Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Inovio Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Inovio Pharmaceuticals stock

What is the equity of Inovio Pharmaceuticals this year?

Inovio Pharmaceuticals has equity of 117.35 M USD this year.

What was the equity of Inovio Pharmaceuticals compared to the previous year?

The equity of Inovio Pharmaceuticals has increased/decreased by -47.23% decreased compared to the previous year.

What impact does a high equity have on investors of Inovio Pharmaceuticals?

A high equity is advantageous for investors of Inovio Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Inovio Pharmaceuticals?

A low equity can be a risk for investors of Inovio Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Inovio Pharmaceuticals affect the company?

An increase in equity of Inovio Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Inovio Pharmaceuticals affect the company?

A reduction in equity of Inovio Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Inovio Pharmaceuticals?

Some factors that can affect the equity of Inovio Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Inovio Pharmaceuticals so important for investors?

The equity of Inovio Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Inovio Pharmaceuticals take to change the equity?

To change equity, Inovio Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Inovio Pharmaceuticals pay?

Over the past 12 months, Inovio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inovio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Inovio Pharmaceuticals?

The current dividend yield of Inovio Pharmaceuticals is .

When does Inovio Pharmaceuticals pay dividends?

Inovio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inovio Pharmaceuticals?

Inovio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Inovio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inovio Pharmaceuticals located?

Inovio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inovio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inovio Pharmaceuticals from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Inovio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Inovio Pharmaceuticals in the year 2023?

In the year 2023, Inovio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Inovio Pharmaceuticals pay out the dividend?

The dividends of Inovio Pharmaceuticals are distributed in USD.